 Home > Active Ingredient News > Antitumor Therapy > Oncologist: Global multicenter real-world exploration of the efficacy of EGFR-TKIs in patients with rare EGFR-mutant NSCLC

Oncologist: Global multicenter real-world exploration of the efficacy of EGFR-TKIs in patients with rare EGFR-mutant NSCLC

 Last Update: 2022-04-22
 Source: Internet
 Author: User

Tags

photodynamic therapy cancer

nickel rare

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are the standard of care for patients with common sensitive EGFR mutation-positive ((Del19 or L858R)) non-small cell lung cancer (NSCLC); however, 7%-23% of NSCLC tumors Rare EGFR mutations are present
.

These mutations are highly heterogeneous, and the development of detection techniques can help identify mutations with little or no clinical data

The study is a global multicenter retrospective study with endpoints including time to treatment failure (TTF), objective response rate (ORR) and overall survival (OS)
.

Overall, the study included 246 patients (median age: 69.
5 years; Asia: 84%) from nine countries
.

The median time from diagnosis to initiation of exponential therapy was 0.

Overall, the study included 246 patients (median age: 69.

Patients were divided into 4 groups according to mutation type: major rare mutation (72.
8%), exon 20 insertion (11.
8%), other rare mutation (8.
5%) and T790M mutation (6.
9%)
.

Major rare mutation (72.

After a median follow-up of 19.
1 months (IQR, 10.
5-31.
3), median TTF was 9.
9 months (95% CI, 7.
8-11.
6) and median OS was 24.
4 months (95% CI) in patients treated with targeted EGFR TKIs , 20.
2-28.
2)
.

For patients who received EGFR TKIs as first-line therapy, the median TTF was 10.

After a median follow-up of 19.

On afatinib treatment, the median TTF was 5.
7 months in the T790M group and 14.
3 months in the major rare mutation group, of which 30.
4% had T790M or exon 20 insertion mutations
.

The median OS for patients in the major rare mutation group was 2 years

On afatinib treatment, the median TTF was 5.

The ORR was 43.
4% in patients treated with the target EGFR TKI, and the median duration of response was 10.
0 months (IQR, 5.
0-16.
0)
.

The ORR of afatinib was 43.
8% (median time to response: 12.
0 months) and the ORR of first-generation EGFR TKIs was 44.
1% (median time to response: 6.
0 months)
.

The ORR was 43.
4% in patients treated with the target EGFR TKI, and the median duration of response was 10.
0 months (IQR, 5.
0-16.
0)
.
The ORR of afatinib was 43.
8% (median time to response: 12.
0 months) and the ORR of first-generation EGFR TKIs was 44.
1% (median time to response: 6.
0 months)
.
The ORR was 43.
4% in patients treated with the target EGFR TKI, and the median duration of response was 10.
0 months (IQR, 5.
0-16.
0)
.
The ORR of afatinib was 43.
8% (median time to response: 12.
0 months) and the ORR of first-generation EGFR TKIs was 44.
1% (median time to response: 6.
0 months)
.

In conclusion, this real-world study shows that EGFR-TKI is still a commonly used treatment in NSCLC patients with rare EGFR mutations, and significant efficacy is still seen in the main rare mutation and mixed mutation types
.
This real-world study shows that EGFR-TKIs are still commonly used in NSCLC patients with rare EGFR mutations, and significant efficacy is still seen for the main rare mutation and mixed mutation types
.
This real-world study shows that EGFR-TKIs are still commonly used in NSCLC patients with rare EGFR mutations, and significant efficacy is still seen for the main rare mutation and mixed mutation types
.

Original source:

Popat S, Hsia TC, Hung JY, Jung HA, Shih JY, Park CK, Lee SH, Okamoto T, Ahn HK, Lee YC, Sato Y, Lee SS, Mascaux C, Daoud H, Märten A, Miura S.
Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG).
Oncologist.
2022 Mar 11:oyac022.
doi: 10.
1093/oncolo/oyac022.
Epub ahead of print.
PMID: 35274704.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.